Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management

被引：683

作者：

Kyle, R. A. ^{[1
]}

Durie, B. G. M. ^{[2
]}

Rajkumar, S. V. ^{[1
]}

Landgren, O. ^{[3
]}

Blade, J. ^{[4
]}

Merlini, G. ^{[5
]}

Kroeger, N. ^{[6
]}

Einsele, H. ^{[7
]}

Vesole, D. H. ^{[8
]}

Dimopoulos, M. ^{[9
]}

San Miguel, J. ^{[10
]}

Avet-Loiseau, H. ^{[11
]}

Hajek, R. ^{[12
]}

Chen, W. M. ^{[13
]}

Anderson, K. C. ^{[14
]}

Ludwig, H. ^{[15
]}

Sonneveld, P. ^{[16
]}

Pavlovsky, S. ^{[17
]}

Palumbo, A. ^{[18
]}

Richardson, P. G. ^{[14
]}

Barlogie, B. ^{[19
,20
]}

Greipp, P. ^{[1
]}

Vescio, R. ^{[2
]}

Turesson, I. ^{[21
]}

Westin, J. ^{[22
]}

Boccadoro, M. ^{[18
]}

机构：

[1] Mayo Clin, Div Hematol, Rochester, MN 55905 USA

[2] Samuel Oschin Comprehens Canc Inst, Cedars Sinai Outpatient Canc Ctr, Aptium Oncol Inc, Los Angeles, CA USA

[3] NCI, NIH, Bethesda, MD 20892 USA

[4] Hosp Clin Barcelona, IDIBAPS, Dept Hematol, Barcelona, Spain

[5] Univ Hosp San Matteo, Dept Biochem, Pavia, Italy

[6] Univ Hamburg Hosp, Dept Stem Cell Transplantat, D-2000 Hamburg, Germany

[7] Univ Wurzburg, Dept Internal Med, Wurzburg, Germany

[8] Hackensack Univ Med Ctr, Hackensack Canc Ctr, Hackensack, NJ USA

[9] Univ Athens, Sch Med, Dept Therapeut, GR-11527 Athens, Greece

[10] Hosp Univ Salamanca, IBMCC USAL CSIC Salamanca, Serv Hematol, Dept Hematol,CIC, Salamanca, Spain

[11] Inst Biol, Hematol Lab, Nantes, France

[12] Univ Hosp Brno, Dept Internal Med Hematol, Brno, Czech Republic

[13] Beijing Chaoyang Hosp, Dept Hematol & Oncol, Beijing, Peoples R China

[14] Dana Farber Canc Inst, Dept Med Oncol, Div Hematol Malignancies, Boston, MA 02115 USA

[15] Wilhelminenspital Stadt Wien, Ctr Oncol & Hematol, Dept Med 1, Vienna, Austria

[16] Erasmus MC, Dept Hematol, Rotterdam, Netherlands

[17] Angel Ocampo Hosp, FUNDALEU, Buenos Aires, DF, Argentina

[18] Univ Turin, Div Ematol, Turin, Italy

[19] MIRT UAMS, Dept Hematol, Little Rock, AR USA

[20] MIRT UAMS, Dept Pathol, Little Rock, AR USA

[21] Malmo Univ Hosp, Dept Hematol, Malmo, Sweden

[22] Sahlgrens Univ Hosp, Dept Hematol, Gottenburg, Sweden

来源：

LEUKEMIA | 2010年 / 24卷 / 06期

关键词：

monoclonal gammopathy of undetermined significance; smoldering multiple myeloma; International Myeloma Working Group; MGUS; LIGHT-CHAIN RATIO; MALIGNANT-TRANSFORMATION; FLOW-CYTOMETRY; PLASMA-CELLS; LONG-TERM; PREVALENCE; RECOGNITION; PROGNOSIS; CRITERIA; BONE;

D O I：

10.1038/leu.2010.60

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 [肿瘤学];

摘要：

Monoclonal gammopathy of undetermined significance (MGUS) was identified in 3.2% of 21 463 residents of Olmsted County, Minnesota, 50 years of age or older. The risk of progression to multiple myeloma, Waldenstrom's macroglobulinemia, AL amyloidosis or a lymphoproliferative disorder is approximately 1% per year. Low-risk MGUS is characterized by having an M protein < 15 g/l, IgG type and a normal free light chain (FLC) ratio. Patients should be followed with serum protein electrophoresis at six months and, if stable, can be followed every 2-3 years or when symptoms suggestive of a plasma cell malignancy arise. Patients with intermediate and high-risk MGUS should be followed in 6 months and then annually for life. The risk of smoldering (asymptomatic) multiple myeloma (SMM) progressing to multiple myeloma or a related disorder is 10% per year for the first 5 years, 3% per year for the next 5 years and 1-2% per year for the next 10 years. Testing should be done 2-3 months after the initial recognition of SMM. If the results are stable, the patient should be followed every 4-6 months for 1 year and, if stable, every 6-12 months. Leukemia (2010) 24, 1121-1127; doi:10.1038/leu.2010.60; published online 22 April 2010

引用

页码：1121 / 1127

页数：7

共 23 条

[1]

Clinically relevant end points and new drug approvals for myeloma [J].